Sanjeeta Sitaula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sanjeeta Sitaula has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Rajeev Ojha
Department of Neurology Tribhuvan University Institute of Medicine Teaching Hospital Kathmandu Nepal
4 shared publications Ananda Kumar Sharma
3 shared publicationsAk Sharma
Department of Ophthalmology, B. P. Koirala Lions Centre for Ophthalmic Studies
2 shared publicationsBipin Koirala
Maharajgunj Medical Campus, Institute of Medicine Tribhuvan University Maharajgunj Nepal
2 shared publications- Hira Nath Dahal
B.P.Koirala Lions Centre for Ophthalmic Sciences, Maharajgunj Medical Campus, Institute of Medicine
2 shared publications Manisha Dahal
Glasgow Caledonian University, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1)
Analysis of retinal nerve fiber layer, ganglion cell complex and visual field in pituitary adenoma
- 14 November 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1)
Open AccessAnalysis of retinal nerve fiber layer, ganglion cell complex and visual field in pituitary adenoma
- Open Access
- 30 April 2025
- Published by Birat Medical College and Teaching Hospital in Birat Journal of Health Sciences
- Vol. 10 (1) , 82-88
Visual Function In Ethambutol Induced Optic Neuropathy At a Tertiary Eye Centre: A Retrospective Study
Introduction: Ethambutol is an important and widely used drug in the treatment of both tubercular and non-tubercular mycobacterial disease as it is the least toxic of the first line antituberculosis drugs. The main disadvantage of this drug is its associated ocular toxicity, manifesting as optic neuropathy. Objectives: To describe the demography, risk factors and visual function in Ethambutol induced Optic Neuropathy (EON) among patients presenting at a tertiary eye centre in Nepal. Methodology: This retrospective study was conducted at B.P. Koirala Lions Centre for Ophthalmic Studies, Institute of Medicine, where all consecutive patients with ethambutol induced optic neuropathy presenting from 1st April 2022 to 30th March 2024 were recorded. Parameters recorded were patient demographics (age, gender and ethnicity), presenting complaints, duration and dosages of ethambutol, body weight, visual acuity, colour vision, contrast sensitivity and visual field. Results: There were 14 patients (28 eyes) of ethambutol induced optic neuropathy. The mean age of patients taking ethambutol was 50.64± 15.8 years with mean daily dose of 18.27 ± 2.29 mg/kg per day. Bilateral ocular involvement was seen with visual acuity ranging from CFCF to 20/60 in one or both eyes. The most common color vision defect was nonspecific defect seen in six patients. The most common visual field defect was centrocecal scotoma in six cases. Mean contrast sensitivity was 1.50±0.32 log units. Thinning of the RNFL and GCC were seen in all cases of EON and the thinning correlated with the severity of visual loss. Conclusions: EON was seen at a mean dose of 18.27mg/kg and mean duration of 7.25 months with moderate to severe visual loss and decrease in contrast sensitivity and visual field defects. Average RNFL thinning and GCC thinning correlated with the severity of visual loss seen in EON subjects. Awareness and early diagnosis can help reduce the unnecessary blindness due to this condition in the susceptible group.
- 30 April 2025
- Published by Birat Medical College and Teaching Hospital in Birat Journal of Health Sciences
- Vol. 10 (1) , 82-88
Open AccessVisual Function In Ethambutol Induced Optic Neuropathy At a Tertiary Eye Centre: A Retrospective Study
Introduction: Ethambutol is an important and widely used drug in the treatment of both tubercular and non-tubercular mycobacterial disease as it is the least toxic of the first line antituberculosis drugs. The main disadvantage of this drug is its associated ocular toxicity, manifesting as optic neuropathy. Objectives: To describe the demography, risk factors and visual function in Ethambutol induced Optic Neuropathy (EON) among patients presenting at a tertiary eye centre in Nepal. Methodology: This retrospective study was conducted at B.P. Koirala Lions Centre for Ophthalmic Studies, Institute of Medicine, where all consecutive patients with ethambutol induced optic neuropathy presenting from 1st April 2022 to 30th March 2024 were recorded. Parameters recorded were patient demographics (age, gender and ethnicity), presenting complaints, duration and dosages of ethambutol, body weight, visual acuity, colour vision, contrast sensitivity and visual field. Results: There were 14 patients (28 eyes) of ethambutol induced optic neuropathy. The mean age of patients taking ethambutol was 50.64± 15.8 years with mean daily dose of 18.27 ± 2.29 mg/kg per day. Bilateral ocular involvement was seen with visual acuity ranging from CFCF to 20/60 in one or both eyes. The most common color vision defect was nonspecific defect seen in six patients. The most common visual field defect was centrocecal scotoma in six cases. Mean contrast sensitivity was 1.50±0.32 log units. Thinning of the RNFL and GCC were seen in all cases of EON and the thinning correlated with the severity of visual loss. Conclusions: EON was seen at a mean dose of 18.27mg/kg and mean duration of 7.25 months with moderate to severe visual loss and decrease in contrast sensitivity and visual field defects. Average RNFL thinning and GCC thinning correlated with the severity of visual loss seen in EON subjects. Awareness and early diagnosis can help reduce the unnecessary blindness due to this condition in the susceptible group.
- Open Access
- 13 February 2025
- Published by Elsevier in The Ocular Surface
- Vol. 37, 11-23
The impact of dry eye disease on patient-reported quality of life: A Save Sight Dry Eye Registry study
- 13 February 2025
- Published by Elsevier in The Ocular Surface
- Vol. 37, 11-23
Open AccessThe impact of dry eye disease on patient-reported quality of life: A Save Sight Dry Eye Registry study
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Ophthalmological Medicine
- Vol. 2025 (1) , 6694537
Neuro‐Ophthalmic Manifestation Associated With COVID‐19 in a Tertiary Eye Center in Nepal
The coronavirus disease 2019 (COVID‐19) primarily involves the respiratory system, but can manifest with a variety of neuro‐ophthalmic symptoms. Here, we describe three cases presenting with neuro‐ophthalmic manifestations secondary to COVID‐19 at a tertiary center in Nepal. The first case was a 42‐year‐old male with sudden onset painless loss of vision noticed in the right eye (RE) after COVID‐19 infection. Examination findings in the RE showed best corrected visual acuity (BCVA) of 6/18 with relative afferent pupillary defect positive and superior sectoral disk edema in the same eye. The case was diagnosed as RE nonarteritic ischemic optic neuropathy associated with COVID‐19 infection. Our second case was a 41‐year‐old female who developed bilateral sudden diminution of vision associated with headache and vomiting on the third day of testing positive for COVID‐19 infection. She had bilateral BCVA of 6/12 and sluggishly reacting pupils in both eyes. Dilated fundus examination showed established disk edema. Imaging of the brain showed dural venous sinus (transverse and sagittal) thrombosis. So, the diagnosis of papilledema secondary to COVID‐19 associated cerebral venous sinus thrombosis (CVST) was established. The third case was a 40‐year‐old male with right sixth cranial nerve palsy, ischemic stroke involving the right occipital lobe and posterior limb of the right internal capsule along with thrombosis of the left common iliac artery in the absence of any other preexisting vascular risk factors. Severe inflammatory reaction to COVID‐19 causing a hypercoagulable state may be the causal factor in neuro‐ophthalmic findings in our case series.
- 1 January 2025
- Published by Wiley in Case Reports in Ophthalmological Medicine
- Vol. 2025 (1) , 6694537
Open AccessNeuro‐Ophthalmic Manifestation Associated With COVID‐19 in a Tertiary Eye Center in Nepal
The coronavirus disease 2019 (COVID‐19) primarily involves the respiratory system, but can manifest with a variety of neuro‐ophthalmic symptoms. Here, we describe three cases presenting with neuro‐ophthalmic manifestations secondary to COVID‐19 at a tertiary center in Nepal. The first case was a 42‐year‐old male with sudden onset painless loss of vision noticed in the right eye (RE) after COVID‐19 infection. Examination findings in the RE showed best corrected visual acuity (BCVA) of 6/18 with relative afferent pupillary defect positive and superior sectoral disk edema in the same eye. The case was diagnosed as RE nonarteritic ischemic optic neuropathy associated with COVID‐19 infection. Our second case was a 41‐year‐old female who developed bilateral sudden diminution of vision associated with headache and vomiting on the third day of testing positive for COVID‐19 infection. She had bilateral BCVA of 6/12 and sluggishly reacting pupils in both eyes. Dilated fundus examination showed established disk edema. Imaging of the brain showed dural venous sinus (transverse and sagittal) thrombosis. So, the diagnosis of papilledema secondary to COVID‐19 associated cerebral venous sinus thrombosis (CVST) was established. The third case was a 40‐year‐old male with right sixth cranial nerve palsy, ischemic stroke involving the right occipital lobe and posterior limb of the right internal capsule along with thrombosis of the left common iliac artery in the absence of any other preexisting vascular risk factors. Severe inflammatory reaction to COVID‐19 causing a hypercoagulable state may be the causal factor in neuro‐ophthalmic findings in our case series.
- Open Access
- 21 July 2023
- Published by Nepal Journals Online (JOL) in Nepal Journal of Neuroscience
- Vol. 20 (2) , 49-56
Visual field defects in neuro-ophthalmological diseases at a tertiary hospital in Nepal
Purpose: This retrospective study aims to describe the pattern of visual field defects among patients presenting with neuro-ophthalmological diseases in a tertiary hospital of Kathmandu. Materials and Methods: Medical records of patients undergoing Goldmann visual fields (GVF) for neuro-ophthalmological diseases from July 2019 to June 2021 were retrospectively reviewed. Patient demographics, laterality of the disease, clinical diagnosis and pattern of visual field defect were evaluated and entered and analyzed using SPSS version 20 using descriptive univariate and bivariate analysis. Results: A total of 216 subjects (378 eyes) with the mean age 34.52±14.80 years were included in the study. The visual field defects were divided 4 categories: optic nerve disorders (76.4%, n=165), chiasmal disorders (17.6%, n=38), retrochiasmal disorders (2.8%, n=6) and miscellaneous (3.2%, n=7). Disc edema/papilledema was the most common diagnosis in optic nerve disorders with enlarged blind spot (79.1%) and constriction of visual fields (18.3%) as pattern of visual field defects followed by optic neuritis. Common lesions affecting the chiasma in our study were craniopharyngioma on whom 50% had the classical temporal field involvement (bitemporal-20%, inferotemporal-20% and superotemporal-10%) and pituitary lesions where 30% showed constriction of peripheral fields, 57.5% showed temporal field defects (mostly superotemporal) in both eyes. Retrochiasmal lesions were less common but all showed a bilateral and homonymous pattern of visual field defect. Conclusion: Optic nerve disorders were the most common group of conditions undergoing visual fields. Understanding the varied patterns of visual field defects can aid in early diagnosis and guide timely treatment of common neuro-ophthalmological diseases.
- 21 July 2023
- Published by Nepal Journals Online (JOL) in Nepal Journal of Neuroscience
- Vol. 20 (2) , 49-56
Open AccessVisual field defects in neuro-ophthalmological diseases at a tertiary hospital in Nepal
Purpose: This retrospective study aims to describe the pattern of visual field defects among patients presenting with neuro-ophthalmological diseases in a tertiary hospital of Kathmandu. Materials and Methods: Medical records of patients undergoing Goldmann visual fields (GVF) for neuro-ophthalmological diseases from July 2019 to June 2021 were retrospectively reviewed. Patient demographics, laterality of the disease, clinical diagnosis and pattern of visual field defect were evaluated and entered and analyzed using SPSS version 20 using descriptive univariate and bivariate analysis. Results: A total of 216 subjects (378 eyes) with the mean age 34.52±14.80 years were included in the study. The visual field defects were divided 4 categories: optic nerve disorders (76.4%, n=165), chiasmal disorders (17.6%, n=38), retrochiasmal disorders (2.8%, n=6) and miscellaneous (3.2%, n=7). Disc edema/papilledema was the most common diagnosis in optic nerve disorders with enlarged blind spot (79.1%) and constriction of visual fields (18.3%) as pattern of visual field defects followed by optic neuritis. Common lesions affecting the chiasma in our study were craniopharyngioma on whom 50% had the classical temporal field involvement (bitemporal-20%, inferotemporal-20% and superotemporal-10%) and pituitary lesions where 30% showed constriction of peripheral fields, 57.5% showed temporal field defects (mostly superotemporal) in both eyes. Retrochiasmal lesions were less common but all showed a bilateral and homonymous pattern of visual field defect. Conclusion: Optic nerve disorders were the most common group of conditions undergoing visual fields. Understanding the varied patterns of visual field defects can aid in early diagnosis and guide timely treatment of common neuro-ophthalmological diseases.
- 1 June 2023
- Published by Lumbini Medical College in Journal of Lumbini Medical College
- Vol. 11 (1)
Ocular Manifestations in Patients with Extrapulmonary Tuberculosis
Introduction : The study was done to find out the ocular manifestation in patients with extrapulmonary tuberculosis visiting a tertiary eye centre. Methods: A hospital based descriptive observational study was done among newly diagnosed extrapulmonary tuberculosis cases after approval from the institutional review board. After a detailed ocular evaluation, findings including patient demographics, presenting complaints, best corrected visual acuity, colour vision, contrast sensitivity, Goldman visual field and Optical Coherence tomography Retinal nerve fibre layer analysis of the optic nerve head were recorded in a semi-structured proforma. Data were expressed in frequency and percentage. Results: Out of 50 eyes of 25 patients included in the study, the mean age was 26.92±14.2 years (11-73 years). Sixty four percent were female. Two cases had ocular findings at the time of diagnosis. One case of tuberculous lymphadenitis had phlyctenular conjunctivitis and one case of tubercular meningitis had diplopia with right lateral rectus muscle paresis secondary to raised intracranial pressure. All the patients had best corrected visual acuity better than 6/12 at presentation. Color vision was normal in 72% cases in both eyes. Goldman visual field done at presentation were normal in both eyes in 88% cases while retinal nerve fibre layer thickness and contrast sensitivity were normal in all cases. Conclusion: The prevalence of ocular findings in patients with extrapulmonary tuberculosis was 8% in this study. Ocular examination is important in cases with extrapulmonary tuberculosis since a significant number of cases have ocular findings.
- 1 June 2023
- Published by Lumbini Medical College in Journal of Lumbini Medical College
- Vol. 11 (1)
Ocular Manifestations in Patients with Extrapulmonary Tuberculosis
Introduction : The study was done to find out the ocular manifestation in patients with extrapulmonary tuberculosis visiting a tertiary eye centre. Methods: A hospital based descriptive observational study was done among newly diagnosed extrapulmonary tuberculosis cases after approval from the institutional review board. After a detailed ocular evaluation, findings including patient demographics, presenting complaints, best corrected visual acuity, colour vision, contrast sensitivity, Goldman visual field and Optical Coherence tomography Retinal nerve fibre layer analysis of the optic nerve head were recorded in a semi-structured proforma. Data were expressed in frequency and percentage. Results: Out of 50 eyes of 25 patients included in the study, the mean age was 26.92±14.2 years (11-73 years). Sixty four percent were female. Two cases had ocular findings at the time of diagnosis. One case of tuberculous lymphadenitis had phlyctenular conjunctivitis and one case of tubercular meningitis had diplopia with right lateral rectus muscle paresis secondary to raised intracranial pressure. All the patients had best corrected visual acuity better than 6/12 at presentation. Color vision was normal in 72% cases in both eyes. Goldman visual field done at presentation were normal in both eyes in 88% cases while retinal nerve fibre layer thickness and contrast sensitivity were normal in all cases. Conclusion: The prevalence of ocular findings in patients with extrapulmonary tuberculosis was 8% in this study. Ocular examination is important in cases with extrapulmonary tuberculosis since a significant number of cases have ocular findings.
- Open Access
- 23 May 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (7) , 3658-3662
Case report peripheral ulcerative keratitis with nodular scleritis, presents as the primary manifestation of granulomatosis with polyangiitis
Introduction and importance: Granulomatosis with polyangiitis (GPA) is an ANCA-associated autoimmune disorder that typically affects small and/or medium-sized blood vessels. Being a life-threatening disease, with timely suspicion, targeted laboratory investigations, and collaborative management from the ophthalmologist and rheumatologist led to long-term remission of the disease. Case: A 38-year-old female complaining of recurrent deep boring pain with redness in her left eye for many years, which was diagnosed as nodular scleritis with peripheral ulcerative keratitis. The patient also has recurrent bouts of epistaxis and in suspicion of GPA laboratory investigations were carried out and later diagnosed. She was started on cyclophosphamide and is currently under maintenance with rituximab. Case discussion: Ocular involvement has been shown to occur in 20–50% of the population in several studies. It causes conjunctivitis, episcleritis, scleritis, necrotizing keratitis, corneoscleral perforation, posterior uveitis, and optic neuritis. The positive C-ANCA and high PR3 autoantibody have high sensitivity and association with GPA. Cyclophosphamide has been shown to be an effective treatment in multiple studies whereas rituximab has been emerging as a new treatment modality for maintenance, which in turn helps in the remission and relapse of GPA cases. Conclusion: Scleritis and peripheral ulcerative keratitis can be the manifestation of a GPA. Careful evaluation, diagnosis, and management with a multidisciplinary medical team, early start of cyclophosphamide, and rituximab have a huge role in decreasing the disease activity and is life-saving.
- 23 May 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (7) , 3658-3662
Open AccessCase report peripheral ulcerative keratitis with nodular scleritis, presents as the primary manifestation of granulomatosis with polyangiitis
Introduction and importance: Granulomatosis with polyangiitis (GPA) is an ANCA-associated autoimmune disorder that typically affects small and/or medium-sized blood vessels. Being a life-threatening disease, with timely suspicion, targeted laboratory investigations, and collaborative management from the ophthalmologist and rheumatologist led to long-term remission of the disease. Case: A 38-year-old female complaining of recurrent deep boring pain with redness in her left eye for many years, which was diagnosed as nodular scleritis with peripheral ulcerative keratitis. The patient also has recurrent bouts of epistaxis and in suspicion of GPA laboratory investigations were carried out and later diagnosed. She was started on cyclophosphamide and is currently under maintenance with rituximab. Case discussion: Ocular involvement has been shown to occur in 20–50% of the population in several studies. It causes conjunctivitis, episcleritis, scleritis, necrotizing keratitis, corneoscleral perforation, posterior uveitis, and optic neuritis. The positive C-ANCA and high PR3 autoantibody have high sensitivity and association with GPA. Cyclophosphamide has been shown to be an effective treatment in multiple studies whereas rituximab has been emerging as a new treatment modality for maintenance, which in turn helps in the remission and relapse of GPA cases. Conclusion: Scleritis and peripheral ulcerative keratitis can be the manifestation of a GPA. Careful evaluation, diagnosis, and management with a multidisciplinary medical team, early start of cyclophosphamide, and rituximab have a huge role in decreasing the disease activity and is life-saving.
- Open Access
- 13 February 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (2) , e6958
Multiple myeloma with plasmacytoma of the clivus bone presenting with multiple cranial nerve III, IV, and VI palsy: A diagnostic dilemma
Central nervous system (CNS) manifestation with cranial nerve palsy in multiple myeloma (MM) is a rare manifestation. Plasmacytoma originates from the bones of the skull base in 3% patients with MM but rarely develops from the soft tissues of the nasal cavity and paranasal sinuses. Here, we present a case of 68‐year‐old male patient with multiple myeloma, clivus bone plasmacytoma, and cavernous sinus syndrome.
- 13 February 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (2) , e6958
Open AccessMultiple myeloma with plasmacytoma of the clivus bone presenting with multiple cranial nerve III, IV, and VI palsy: A diagnostic dilemma
Central nervous system (CNS) manifestation with cranial nerve palsy in multiple myeloma (MM) is a rare manifestation. Plasmacytoma originates from the bones of the skull base in 3% patients with MM but rarely develops from the soft tissues of the nasal cavity and paranasal sinuses. Here, we present a case of 68‐year‐old male patient with multiple myeloma, clivus bone plasmacytoma, and cavernous sinus syndrome.
- Open Access
- 29 January 2023
- Published by Elsevier in Journal of Optometry
- Vol. 16 (3) , 229-235
Agreement between Lea Symbols and Patti Pics visual acuity in children and adults
- 29 January 2023
- Published by Elsevier in Journal of Optometry
- Vol. 16 (3) , 229-235
Open AccessAgreement between Lea Symbols and Patti Pics visual acuity in children and adults
- Open Access
- 31 December 2022
- Published by Nepal Journals Online (JOL) in Nepalese Journal of Ophthalmology
- Vol. 14 (2) , 4-15
Ocular toxicity among patients taking anti-tubercular treatment
Introduction: Tuberculosis remains a major public health problem in Nepal and anti-tubercular drugs used for the treatment of pulmonary and extrapulmonary tuberculosis can be associated with ocular toxicity. This prospective study aimed to evaluate the incidence of ocular toxicity among patients receiving anti-tubercular therapy and to assess the change in visual functions and ocular imaging before and after use of anti-tubercular therapy. Materials and methods: A total of 89 eyes of 45 TB patients taking anti-tubercular therapy were enrolled. Detailed history and examination including best-corrected visual acuity (BCVA), colour vision (Farnsworth D-15t), contrast sensitivity (Pelli-Robson chart), Goldman visual field analysis and spectral domain optical coherence tomography for retinal nerve fibre layer (RNFL) analysis were assessed at baseline and at 6 months after starting anti-tubercular therapy. Visual evoked potential (VEP) was performed in suspected cases. Results: The mean age of the patients was 29.13±14.00 years and 62.2% were males. The mean weight of the subjects was 54.37±10.36 kg, mean daily dosage of ethambutol was 17.91±1.74 mg/day/kg and mean administration duration was 2.71±1.54 months. The incidence of ocular toxicity was 2.24%. Bilateral retrobulbar optic neuropathy occurred in a 27-year female of 55 kg receiving ethambutol (20 mg/kg/day) for 6 months for Pott’s spine. Her best-corrected visual acuity in both eyes was reduced to 6/36 from 6/6 and developed non-specific color vision defect, decreased contrast sensitivity, bilateral cecocentral visual field defect and mean decrease in retinal nerve fibre layer thickness compared to the baseline data. In rest cases, a statistically significant decrease in mean retinal nerve fibre layer thickness in both eyes suggested the evidence of subclinical toxicity. Conclusion: Though less common, ethambutol toxicity can occur in patients under anti-tubercular therapy in the form of retrobulbar optic neuritis. Decreased contrast sensitivity and thinning in the mean retinal nerve fibre layer thickness can be the indicator of subclinical toxicity.
- 31 December 2022
- Published by Nepal Journals Online (JOL) in Nepalese Journal of Ophthalmology
- Vol. 14 (2) , 4-15
Open AccessOcular toxicity among patients taking anti-tubercular treatment
Introduction: Tuberculosis remains a major public health problem in Nepal and anti-tubercular drugs used for the treatment of pulmonary and extrapulmonary tuberculosis can be associated with ocular toxicity. This prospective study aimed to evaluate the incidence of ocular toxicity among patients receiving anti-tubercular therapy and to assess the change in visual functions and ocular imaging before and after use of anti-tubercular therapy. Materials and methods: A total of 89 eyes of 45 TB patients taking anti-tubercular therapy were enrolled. Detailed history and examination including best-corrected visual acuity (BCVA), colour vision (Farnsworth D-15t), contrast sensitivity (Pelli-Robson chart), Goldman visual field analysis and spectral domain optical coherence tomography for retinal nerve fibre layer (RNFL) analysis were assessed at baseline and at 6 months after starting anti-tubercular therapy. Visual evoked potential (VEP) was performed in suspected cases. Results: The mean age of the patients was 29.13±14.00 years and 62.2% were males. The mean weight of the subjects was 54.37±10.36 kg, mean daily dosage of ethambutol was 17.91±1.74 mg/day/kg and mean administration duration was 2.71±1.54 months. The incidence of ocular toxicity was 2.24%. Bilateral retrobulbar optic neuropathy occurred in a 27-year female of 55 kg receiving ethambutol (20 mg/kg/day) for 6 months for Pott’s spine. Her best-corrected visual acuity in both eyes was reduced to 6/36 from 6/6 and developed non-specific color vision defect, decreased contrast sensitivity, bilateral cecocentral visual field defect and mean decrease in retinal nerve fibre layer thickness compared to the baseline data. In rest cases, a statistically significant decrease in mean retinal nerve fibre layer thickness in both eyes suggested the evidence of subclinical toxicity. Conclusion: Though less common, ethambutol toxicity can occur in patients under anti-tubercular therapy in the form of retrobulbar optic neuritis. Decreased contrast sensitivity and thinning in the mean retinal nerve fibre layer thickness can be the indicator of subclinical toxicity.